^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ENO1 deletion

    i
    Other names: ENO1, Enolase 1, Alpha-Enolase, 2-Phospho-D-Glycerate Hydro-Lyase, Plasminogen-Binding Protein, Phosphopyruvate Hydratase, Enolase 1, (Alpha), Non-Neural Enolase, ENO1L1, MBP-1, MPB1, NNE, PPH, Epididymis Secretory Protein Li 17, C-Myc Promoter-Binding Protein-1, MYC Promoter-Binding Protein 1, C-Myc Promoter-Binding Protein, Alpha Enolase Like 1, Tau-Crystallin, Enolase-Alpha, HEL-S-17, MBPB1, MPB-1
    Entrez ID:
    2023
    Related biomarkers:
    CNA
    1year
    Knockdown of ENO1 promotes autophagy dependent-ferroptosis and suppresses glycolysis in breast cancer cells via the regulation of CST1. (PubMed, Drug Dev Res)
    In vivo experiments illustrated that ENO1 deletion suppressed BC tumor growth, increased the apoptosis rate, restrained cell proliferation, and glycolysis, but promoted ferroptosis and autophagy, as well as reducing CST1 and mTOR signaling. To sum up, ENO1 silencing mediated a utophagy-dependent ferroptosis and glycolysis in BC cells by regulating CST1.
    Journal
    |
    ENO1 (Enolase 1)
    |
    ENO1 deletion
    almost2years
    ENO1 deletion potentiates ferroptosis and decreases glycolysis in colorectal cancer cells via AKT/STAT3 signaling. (PubMed, Exp Ther Med)
    The AKT activator SC79 partially reversed the effects of ENO1 deficiency on the AKT/STAT3 signaling, glycolysis, proliferation as well as ferroptosis in CRC cells. In summary, inactivation of AKT/STAT3 signaling mediated by ENO1 inhibition might boost the ferroptosis and suppress the glycolysis in CRC cells.
    Journal
    |
    ENO1 (Enolase 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    ENO1 deletion
    4years
    Histologic, Immunohistochemical and Molecular Stratification of Thymic Neuroendocrine Neoplasms (USCAP 2022)
    In our cohort, all LCNEC were reclassified as G2/G3 WD-NET by morphology and Ki67 index using WHO GEP NEN criteria. G3 WD-NET appears along a molecular spectrum with G2 WD-NET, and biologically distinct from high grade NEC in the thymus. Thymic NENs may be stratified into at least 3 molecular subgroups, including a subset of G3 WD-NET with RAS/MAPK pathway mutations, with potential therapeutic implications.
    TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • KDR (Kinase insert domain receptor) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • TSC1 (TSC complex subunit 1) • FGF4 (Fibroblast growth factor 4) • ENO1 (Enolase 1) • CHD4 (Chromodomain Helicase DNA Binding Protein 4) • DAXX (Death-domain associated protein) • MEN1 (Menin 1) • MAP2K7 (Mitogen-Activated Protein Kinase Kinase 7)
    |
    NRAS mutation • TP53 wild-type • HRAS mutation • TSC1 mutation • MTOR mutation • TP53 expression • ENO1 deletion
    |
    Oncomine™ Comprehensive Assay Plus